168极速一分钟赛车官方入口 Buy and sell Covalent (CQT)

CoinList users

Don't have a CoinList account?

Covalent provides a unified API to bring full transparency and visibility to assets across all blockchain networks. It is a single API that allows you to pull detailed, granular blockchain transaction data from multiple blockchains with no code.

What makes Covalent unique?

There are many elements of the Covalent which make us unique in the marketplace. However, our core differentiators from projects like the Graph are:

1. Data availability

We are the only project to fully index entire blockchains – this means every single contract, every single wallet address, and every single transaction. This is billions of rows of data and terabytes of data. Other projects only provide a small subset of the available data or only start collecting data once the appropriate query or filter is set up.

2. Composability

Composability is a critical piece of Decentralized Finance (DeFi) applications and allows developers to quickly and easily construct financial solutions leveraging ‘Lego-like’ building blocks from a multitude of projects. The multichain flexiblity and deep, granular data provided by our APIs means developers can quickly and easily build scalable and data rich applications with no query code.

3. Multi-blockchain support

Multichain is in our DNA. Covalent already indexes and has customers on 7 different blockchain networks with many more to announce soon.

4. No code solution

We believe in no-code solutions for our users. This means no complicated SQL queries, no subgraph development and maintenance, and no need to invest in highly-skilled (read expensive) developers to simply retrieve blockchain data, which is a monumental waste of engineering time. One API and you are done.

Recent News

Covalent PR Newswire Covalent

BridGene Biosciences Announces Acceptance of Two Abstracts for Poster Presentations at Cambridge Health Institute's Inaugural Drug Discovery Chemistry Conference

Apr 14 · PR Newswire · SAN JOSE, Calif., April 14, 2022 /PRNewswire/ -- BridGene Biosciences, Inc., a biotechnology company using a unique chemoproteomic technology to discover and develop small molecules for high value, traditionally undruggable targets, today announced that two abstracts have been accepted for poster presentation during the Cambridge Health Institute's Inaugural Drug Discovery Chemistry Conference taking place April 18-21, 2022 in San Diego, California.

Covalent PR Newswire Covalent

Covalent Metrology Expands its Electron Microscopy Capabilities

Apr 14 · PR Newswire · The Growing Electron Microscopy Group at Covalent's Silicon Valley lab significantly expands its team and instrument portfolio for FIB-SEM and S/TEM analysis.

Covalent PR Newswire Covalent

Covalent Metrology Expands its Electron Microscopy Capabilities

Apr 14 · PR Newswire · The Growing Electron Microscopy Group at Covalent's Silicon Valley lab significantly expands its team and instrument portfolio for FIB-SEM and S/TEM analysis.

Covalent Coin Telegraph Covalent

Crypto mixers’ relevance wanes as regulators take aim

Apr 12 · Coin Telegraph · Cryptocurrency mixers have been an interesting topic of discussion ever since the advent of cryptocurrencies and their adoption by retail investors around the world.

6 Shares

Covalent PR Newswire Covalent

Vivace Therapeutics Presents New Preclinical Data Highlighting Strong Synergistic Activity for Combination of VT3989 and Osimertinib at American Association for Cancer Research (AACR) Annu...

Apr 11 · PR Newswire · Combination Treatment Demonstrates Enhanced Efficacy and Delayed Tumor Growth as Compared to Osimertinib Alone in EGFR Mutant Non-Small Cell Lung Cancer Models VT3989, a First-in-Class TEAD Autopalmitoylation Inhibitor, Currently Being Evaluated in Phase 1 Clinical Trials SAN MATEO, Calif. , April 11, 2022 /PRNewswire/ -- Vivace Therapeutics, Inc., a small molecule discovery and development company developing first-in-class therapies targeting the Hippo pathway, today announced that new preclinical data on the company's transcriptional enhanced associate domain (TEAD) autopalmitoylation inhibitor, VT3989, were reported at the American Association for Cancer Research (AACR) Annual Meeting 2022.